PT2067775E - Inibidor de n-acil-esfingosina-glucosiltransferase - Google Patents
Inibidor de n-acil-esfingosina-glucosiltransferase Download PDFInfo
- Publication number
- PT2067775E PT2067775E PT09003291T PT09003291T PT2067775E PT 2067775 E PT2067775 E PT 2067775E PT 09003291 T PT09003291 T PT 09003291T PT 09003291 T PT09003291 T PT 09003291T PT 2067775 E PT2067775 E PT 2067775E
- Authority
- PT
- Portugal
- Prior art keywords
- acylsphingosine glucosyltransferase
- glucosyltransferase inhibitor
- acylsphingosine
- disclosed
- synthesis
- Prior art date
Links
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 title abstract 2
- 229940122959 Glucosyltransferase inhibitor Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 102000000340 Glucosyltransferases Human genes 0.000 abstract 1
- 108010055629 Glucosyltransferases Proteins 0.000 abstract 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 abstract 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30581401P | 2001-07-16 | 2001-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2067775E true PT2067775E (pt) | 2012-07-16 |
Family
ID=23182463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT09003291T PT2067775E (pt) | 2001-07-16 | 2002-07-16 | Inibidor de n-acil-esfingosina-glucosiltransferase |
| PT02750099T PT1409467E (pt) | 2001-07-16 | 2002-07-16 | Inibidor de n-acil-esfingosina-glucosiltransferase |
| PT100754290T PT2266968E (pt) | 2001-07-16 | 2002-07-16 | Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02750099T PT1409467E (pt) | 2001-07-16 | 2002-07-16 | Inibidor de n-acil-esfingosina-glucosiltransferase |
| PT100754290T PT2266968E (pt) | 2001-07-16 | 2002-07-16 | Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase |
Country Status (15)
| Country | Link |
|---|---|
| US (11) | US6855830B2 (pt) |
| EP (3) | EP2266968B1 (pt) |
| JP (6) | JP5038582B2 (pt) |
| AT (2) | ATE554082T1 (pt) |
| BE (1) | BE2015C029I2 (pt) |
| BR (3) | BRPI0211379B8 (pt) |
| CA (1) | CA2453978C (pt) |
| CY (1) | CY2015028I1 (pt) |
| DK (3) | DK1409467T3 (pt) |
| ES (3) | ES2399323T3 (pt) |
| FR (1) | FR15C0036I2 (pt) |
| IL (3) | IL159905A0 (pt) |
| LU (1) | LU92717I2 (pt) |
| PT (3) | PT2067775E (pt) |
| WO (1) | WO2003008399A1 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890949B1 (en) * | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CA2434028C (en) | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| IL159905A0 (en) | 2001-07-16 | 2004-06-20 | Genzyme Corp | Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives |
| WO2003045928A1 (en) * | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US20060217560A1 (en) * | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) * | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| JP4195411B2 (ja) * | 2004-04-12 | 2008-12-10 | セイコーエプソン株式会社 | 有機エレクトロルミネッセンス装置の製造方法 |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| AU2006209207C1 (en) | 2005-01-26 | 2013-05-23 | Allergan, Inc. | 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity |
| US8716327B2 (en) | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
| PT2121713E (pt) | 2007-01-18 | 2013-06-25 | Genzyme Corp | Oligossacáridos compreendendo um grupo aminooxi e seus conjugados |
| US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| US8173683B2 (en) | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| PT2481407T (pt) * | 2007-03-06 | 2018-12-28 | Allergan Inc | Compostos para utilização no tratamento de distúrbios cognitivos |
| EP2594563B1 (en) | 2007-05-31 | 2018-07-18 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009045503A1 (en) * | 2007-10-05 | 2009-04-09 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
| US8168631B2 (en) | 2008-02-05 | 2012-05-01 | Allergan, Inc. | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| CA2738768C (en) | 2008-10-03 | 2017-10-31 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| DK3608330T3 (da) | 2008-12-16 | 2023-02-06 | Genzyme Corp | Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater |
| ES2586947T3 (es) * | 2009-11-27 | 2016-10-19 | Genzyme Corporation | Genz 112638 para tratar la enfermedad de Gaucher o de Fabry en terapia de combinación |
| WO2011129448A1 (ja) | 2010-04-16 | 2011-10-20 | 京セラ株式会社 | 無線通信システム、高電力基地局、低電力基地局、及び通信制御方法 |
| JP2014513952A (ja) | 2011-04-22 | 2014-06-19 | ジェンザイム・コーポレーション | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| EP2968268B1 (en) * | 2013-03-15 | 2020-07-29 | Concert Pharmaceuticals Inc. | Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase |
| WO2015042397A1 (en) | 2013-09-20 | 2015-03-26 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| WO2015059679A1 (en) * | 2013-10-25 | 2015-04-30 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of eliglustat |
| MX376685B (es) | 2013-10-29 | 2025-03-07 | Biomarin Pharm Inc | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3-carboxamida como inhibidores de glucosilceramida sintasa. |
| JP6749923B2 (ja) | 2015-02-02 | 2020-09-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | グルコシルセラミドシンターゼ阻害剤及びそれを使用した治療方法 |
| CN104557851B (zh) * | 2015-02-10 | 2017-04-05 | 苏州明锐医药科技有限公司 | 依鲁司他的制备方法 |
| ES2716420T3 (es) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Clorhidrato de eliglustat cristalino |
| WO2017068496A1 (en) * | 2015-10-20 | 2017-04-27 | Dr. Reddy' S Laboratories Limited | Improved process for the preparation of eliglustat and its salts |
| CN105646442A (zh) * | 2015-10-27 | 2016-06-08 | 北京凯莱天成医药科技有限公司 | 一种依利格鲁司他的制备方法 |
| AU2017251256B2 (en) | 2016-04-11 | 2022-06-09 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| CN106967042B (zh) * | 2017-03-21 | 2020-08-14 | 浙江奥翔药业股份有限公司 | 依利格鲁司他的合成方法及其中间体化合物 |
| CN108822072B (zh) * | 2017-04-11 | 2021-01-12 | 中国医学科学院药物研究所 | 一种制备伊力格鲁司他的方法 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| WO2018225085A1 (en) | 2017-06-05 | 2018-12-13 | Cipla Limited | Stable solid dispersions of eliglustat hemitartrate |
| AU2018386182B2 (en) | 2017-12-15 | 2024-03-28 | Genzyme Corporation | Methods for treating Gaucher disease |
| WO2019123476A1 (en) | 2017-12-20 | 2019-06-27 | Sarudbhava Formulations Private Limited | Stable amorphous eliglustat premix and process for the preparation thereof |
| CN111217791B (zh) * | 2018-11-27 | 2024-02-02 | 广东东阳光药业股份有限公司 | 依鲁司他中间体及其制备方法 |
| WO2020194138A1 (en) * | 2019-03-22 | 2020-10-01 | Piramal Enterprises Limited | An improved process for the preparation of eliglustat and its intermediate |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
| US11220479B2 (en) | 2019-10-23 | 2022-01-11 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| WO2021214771A1 (en) | 2020-04-23 | 2021-10-28 | The Israel Institute of Biological Research (IIBR) | Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases |
| WO2021221953A1 (en) | 2020-04-28 | 2021-11-04 | The Regents Of The University Of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
| CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
| EP4201403A1 (en) | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
| WO2026006099A1 (en) | 2024-06-24 | 2026-01-02 | Genzyme Corporation | Eliglustat for the treatment of gaucher disease |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| JPH0416856A (ja) | 1990-05-10 | 1992-01-21 | Canon Inc | 正帯電性非磁性トナー |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| NZ269847A (en) | 1993-08-13 | 1996-11-26 | Seikagaku Kogyo Co Ltd | 2-alkylamino-3-morpholino-1-propanol derivative in a composition for neuronal disease treatment |
| ATE195944T1 (de) | 1994-02-02 | 2000-09-15 | Liposome Co Inc | Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung |
| US5763438A (en) | 1994-06-10 | 1998-06-09 | Seikagaku Corporation | 2-acylaminopropanol compound and medical composition |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20030073680A1 (en) * | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) * | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5916802A (en) * | 1997-02-19 | 1999-06-29 | Fritz Berthold | Device for measuring ATP |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| AU756008B2 (en) | 1998-07-27 | 2003-01-02 | Johns Hopkins University, The | Methods for treating conditions modulated by lactosylceramide |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| CA2434028C (en) | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20020198240A1 (en) * | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| IL159905A0 (en) | 2001-07-16 | 2004-06-20 | Genzyme Corp | Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US8716327B2 (en) * | 2006-05-09 | 2014-05-06 | Genzyme Corporation | Methods of treating fatty liver disease |
-
2002
- 2002-07-16 IL IL15990502A patent/IL159905A0/xx unknown
- 2002-07-16 PT PT09003291T patent/PT2067775E/pt unknown
- 2002-07-16 ES ES10075429T patent/ES2399323T3/es not_active Expired - Lifetime
- 2002-07-16 BR BR0211379-1 patent/BRPI0211379B8/pt active IP Right Grant
- 2002-07-16 CA CA2453978A patent/CA2453978C/en not_active Expired - Lifetime
- 2002-07-16 PT PT02750099T patent/PT1409467E/pt unknown
- 2002-07-16 DK DK02750099.0T patent/DK1409467T3/da active
- 2002-07-16 WO PCT/US2002/022659 patent/WO2003008399A1/en not_active Ceased
- 2002-07-16 ES ES09003291T patent/ES2395463T3/es not_active Expired - Lifetime
- 2002-07-16 EP EP10075429A patent/EP2266968B1/en not_active Expired - Lifetime
- 2002-07-16 EP EP09003291A patent/EP2067775B1/en not_active Expired - Lifetime
- 2002-07-16 PT PT100754290T patent/PT2266968E/pt unknown
- 2002-07-16 US US10/197,227 patent/US6855830B2/en not_active Expired - Lifetime
- 2002-07-16 BR BR122015016313A patent/BR122015016313B8/pt not_active IP Right Cessation
- 2002-07-16 DK DK09003291.3T patent/DK2067775T3/da active
- 2002-07-16 JP JP2003513958A patent/JP5038582B2/ja not_active Expired - Lifetime
- 2002-07-16 AT AT02750099T patent/ATE554082T1/de active
- 2002-07-16 DK DK10075429.0T patent/DK2266968T3/da active
- 2002-07-16 ES ES02750099T patent/ES2395122T3/es not_active Expired - Lifetime
- 2002-07-16 AT AT09003291T patent/ATE555102T1/de active
- 2002-07-16 BR BR122015016314A patent/BR122015016314B8/pt not_active IP Right Cessation
- 2002-07-16 EP EP02750099A patent/EP1409467B1/en not_active Expired - Lifetime
-
2004
- 2004-01-16 IL IL159905A patent/IL159905A/en active Protection Beyond IP Right Term
- 2004-08-12 US US10/916,824 patent/US7265228B2/en not_active Expired - Lifetime
-
2005
- 2005-03-28 US US11/091,836 patent/US7196205B2/en active Active
- 2005-04-08 JP JP2005112378A patent/JP4708073B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-05 US US11/702,425 patent/US7615573B2/en not_active Expired - Lifetime
- 2007-08-24 US US11/895,632 patent/US7763738B2/en not_active Expired - Lifetime
-
2008
- 2008-08-05 IL IL193244A patent/IL193244A0/en unknown
-
2010
- 2010-02-01 JP JP2010020146A patent/JP5227348B2/ja not_active Expired - Lifetime
- 2010-07-06 US US12/830,962 patent/US8138353B2/en not_active Expired - Fee Related
-
2012
- 2012-03-14 US US13/420,108 patent/US8779163B2/en not_active Expired - Lifetime
-
2013
- 2013-02-13 JP JP2013041198A patent/JP2013136618A/ja active Pending
-
2014
- 2014-06-26 US US14/315,453 patent/US9546161B2/en not_active Expired - Fee Related
-
2015
- 2015-04-20 JP JP2015097734A patent/JP2015180656A/ja active Pending
- 2015-05-12 BE BE2015C029C patent/BE2015C029I2/fr unknown
- 2015-05-13 FR FR15C0036C patent/FR15C0036I2/fr active Active
- 2015-05-13 LU LU92717C patent/LU92717I2/xx unknown
- 2015-07-08 CY CY2015028C patent/CY2015028I1/el unknown
-
2016
- 2016-11-09 JP JP2016218570A patent/JP6182254B2/ja not_active Expired - Lifetime
- 2016-12-30 US US15/395,329 patent/US20170334888A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,258 patent/US20190322649A1/en not_active Abandoned
-
2020
- 2020-07-23 US US16/937,437 patent/US20210171507A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2067775E (pt) | Inibidor de n-acil-esfingosina-glucosiltransferase | |
| AU2002348261A1 (en) | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors | |
| HRP20020997A2 (en) | Serine protease inhibitors | |
| PT923554E (pt) | N-benzilpiperidina e derivados tetrahidropiridina | |
| NZ329532A (en) | Diazepino-indoles as phosphodiesterase iv inhibitors | |
| EP1466898A4 (en) | INHIBITORS OF THE PRODUCTION / SEPARATION OF BETA-AMYLOIDS PROTEINS | |
| IL132690A0 (en) | Prostaglandin pharmaceutical compositions | |
| AU5239700A (en) | Process for the synthesis of n-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenyl-sulfon l)-2-hydroxy-2-methyl-propionamide | |
| DE69919436D1 (de) | N-Acyl und N-Aroyl Aralkylamide | |
| AU2003248647A1 (en) | Stereoselective synthesis of 1,2-disubstituted cycloalkyls | |
| PL367774A1 (en) | Synthesis and intermediates | |
| EP1099690A4 (en) | MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM | |
| ATE315026T1 (de) | Amlodipin-hemimaleat | |
| MXPA03006057A (es) | Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil. | |
| CY1113586T1 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
| AU2002320575A1 (en) | Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors | |
| YU62302A (sh) | Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila | |
| NO20042160L (no) | Inhibitorer av 11-betahydroksysteroid dehydrogenase type 1 | |
| AU2000246281A1 (en) | Piperidine compounds and process for providing such | |
| IT1313665B1 (it) | Processo per la produzione di7alfa-alchil-17beta-idrossi-19-norpregn-5(10) | |
| NO20030876D0 (no) | Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin | |
| DE60322856D1 (pt) |